Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection

Robert Svatek, Philippe E. Spiess, Debasish Sundi, Shi Ming Tu, Nizar M. Tannir, Gordon A. Brown, Ashish M. Kamat, Christopher G. Wood, Louis L. Pisters

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Patients with pure teratoma within the postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen traditionally have been considered at low risk for disease progression. The objectives of this study were to determine the disease-related outcomes of patients who had pure teratoma identified at the time of PC-RPLND and to examine the prognostic value of clinical variables that were identified previously as important predictors of disease recurrence in these patients. METHODS: Between 1980 and 2003, 97 patients with metastatic nonseminomatous germ cell tumor and pure teratoma histology at the time of PC-RPLND were identified. The medical records of these patients were reviewed retrospectively for pertinent clinical and treatment-related outcomes. RESULTS: At a median follow-up of 7.4 years, 21 patients (22%) developed recurrent disease after PC-RPLND. The 5-year and 10-year probabilities (±standard error) of freedom from disease recurrence were 81% ± 4% and 76% ± 5%, respectively. The postchemotherapy α-fetoprotein (AFP) level and mediastinal involvement at presentation were statistically significant predictors of disease recurrence on multivariate analysis. Nine of 97 patients (9.3%) died from testis cancer, and 4 patients died from other causes. CONCLUSIONS: In patients with pure teratoma histology at PC-RPLND, mediastinal involvement at presentation and the presence of an elevated AFP level before PC-RPLND predicted an unfavorable outcome. The absence of mediastinal involvement and normal AFP level, however, did not confirm freedom from disease recurrence. Patients who had teratoma at the time of PC-RPLND remained at considerable risk for disease progression because of the unpredictable nature of teratoma and the presence of unrecognized, active germ cell disease outside the retroperitoneum.

Original languageEnglish (US)
Pages (from-to)1310-1317
Number of pages8
JournalCancer
Volume115
Issue number6
DOIs
StatePublished - Mar 15 2009
Externally publishedYes

Fingerprint

Teratoma
Lymph Node Excision
Recurrence
Disease Progression
Histology
Fetal Proteins
Testicular Neoplasms
Germ Cells
Medical Records
Multivariate Analysis

Keywords

  • Outcome
  • Postchemotherapy
  • Predictors
  • Retroperitoneal lymph node dissection
  • Teratoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Svatek, R., Spiess, P. E., Sundi, D., Tu, S. M., Tannir, N. M., Brown, G. A., ... Pisters, L. L. (2009). Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer, 115(6), 1310-1317. https://doi.org/10.1002/cncr.24145

Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. / Svatek, Robert; Spiess, Philippe E.; Sundi, Debasish; Tu, Shi Ming; Tannir, Nizar M.; Brown, Gordon A.; Kamat, Ashish M.; Wood, Christopher G.; Pisters, Louis L.

In: Cancer, Vol. 115, No. 6, 15.03.2009, p. 1310-1317.

Research output: Contribution to journalArticle

Svatek, R, Spiess, PE, Sundi, D, Tu, SM, Tannir, NM, Brown, GA, Kamat, AM, Wood, CG & Pisters, LL 2009, 'Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection', Cancer, vol. 115, no. 6, pp. 1310-1317. https://doi.org/10.1002/cncr.24145
Svatek, Robert ; Spiess, Philippe E. ; Sundi, Debasish ; Tu, Shi Ming ; Tannir, Nizar M. ; Brown, Gordon A. ; Kamat, Ashish M. ; Wood, Christopher G. ; Pisters, Louis L. / Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. In: Cancer. 2009 ; Vol. 115, No. 6. pp. 1310-1317.
@article{168e6b3396a7423cadd42a8e34e69263,
title = "Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection",
abstract = "BACKGROUND: Patients with pure teratoma within the postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen traditionally have been considered at low risk for disease progression. The objectives of this study were to determine the disease-related outcomes of patients who had pure teratoma identified at the time of PC-RPLND and to examine the prognostic value of clinical variables that were identified previously as important predictors of disease recurrence in these patients. METHODS: Between 1980 and 2003, 97 patients with metastatic nonseminomatous germ cell tumor and pure teratoma histology at the time of PC-RPLND were identified. The medical records of these patients were reviewed retrospectively for pertinent clinical and treatment-related outcomes. RESULTS: At a median follow-up of 7.4 years, 21 patients (22{\%}) developed recurrent disease after PC-RPLND. The 5-year and 10-year probabilities (±standard error) of freedom from disease recurrence were 81{\%} ± 4{\%} and 76{\%} ± 5{\%}, respectively. The postchemotherapy α-fetoprotein (AFP) level and mediastinal involvement at presentation were statistically significant predictors of disease recurrence on multivariate analysis. Nine of 97 patients (9.3{\%}) died from testis cancer, and 4 patients died from other causes. CONCLUSIONS: In patients with pure teratoma histology at PC-RPLND, mediastinal involvement at presentation and the presence of an elevated AFP level before PC-RPLND predicted an unfavorable outcome. The absence of mediastinal involvement and normal AFP level, however, did not confirm freedom from disease recurrence. Patients who had teratoma at the time of PC-RPLND remained at considerable risk for disease progression because of the unpredictable nature of teratoma and the presence of unrecognized, active germ cell disease outside the retroperitoneum.",
keywords = "Outcome, Postchemotherapy, Predictors, Retroperitoneal lymph node dissection, Teratoma",
author = "Robert Svatek and Spiess, {Philippe E.} and Debasish Sundi and Tu, {Shi Ming} and Tannir, {Nizar M.} and Brown, {Gordon A.} and Kamat, {Ashish M.} and Wood, {Christopher G.} and Pisters, {Louis L.}",
year = "2009",
month = "3",
day = "15",
doi = "10.1002/cncr.24145",
language = "English (US)",
volume = "115",
pages = "1310--1317",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection

AU - Svatek, Robert

AU - Spiess, Philippe E.

AU - Sundi, Debasish

AU - Tu, Shi Ming

AU - Tannir, Nizar M.

AU - Brown, Gordon A.

AU - Kamat, Ashish M.

AU - Wood, Christopher G.

AU - Pisters, Louis L.

PY - 2009/3/15

Y1 - 2009/3/15

N2 - BACKGROUND: Patients with pure teratoma within the postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen traditionally have been considered at low risk for disease progression. The objectives of this study were to determine the disease-related outcomes of patients who had pure teratoma identified at the time of PC-RPLND and to examine the prognostic value of clinical variables that were identified previously as important predictors of disease recurrence in these patients. METHODS: Between 1980 and 2003, 97 patients with metastatic nonseminomatous germ cell tumor and pure teratoma histology at the time of PC-RPLND were identified. The medical records of these patients were reviewed retrospectively for pertinent clinical and treatment-related outcomes. RESULTS: At a median follow-up of 7.4 years, 21 patients (22%) developed recurrent disease after PC-RPLND. The 5-year and 10-year probabilities (±standard error) of freedom from disease recurrence were 81% ± 4% and 76% ± 5%, respectively. The postchemotherapy α-fetoprotein (AFP) level and mediastinal involvement at presentation were statistically significant predictors of disease recurrence on multivariate analysis. Nine of 97 patients (9.3%) died from testis cancer, and 4 patients died from other causes. CONCLUSIONS: In patients with pure teratoma histology at PC-RPLND, mediastinal involvement at presentation and the presence of an elevated AFP level before PC-RPLND predicted an unfavorable outcome. The absence of mediastinal involvement and normal AFP level, however, did not confirm freedom from disease recurrence. Patients who had teratoma at the time of PC-RPLND remained at considerable risk for disease progression because of the unpredictable nature of teratoma and the presence of unrecognized, active germ cell disease outside the retroperitoneum.

AB - BACKGROUND: Patients with pure teratoma within the postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen traditionally have been considered at low risk for disease progression. The objectives of this study were to determine the disease-related outcomes of patients who had pure teratoma identified at the time of PC-RPLND and to examine the prognostic value of clinical variables that were identified previously as important predictors of disease recurrence in these patients. METHODS: Between 1980 and 2003, 97 patients with metastatic nonseminomatous germ cell tumor and pure teratoma histology at the time of PC-RPLND were identified. The medical records of these patients were reviewed retrospectively for pertinent clinical and treatment-related outcomes. RESULTS: At a median follow-up of 7.4 years, 21 patients (22%) developed recurrent disease after PC-RPLND. The 5-year and 10-year probabilities (±standard error) of freedom from disease recurrence were 81% ± 4% and 76% ± 5%, respectively. The postchemotherapy α-fetoprotein (AFP) level and mediastinal involvement at presentation were statistically significant predictors of disease recurrence on multivariate analysis. Nine of 97 patients (9.3%) died from testis cancer, and 4 patients died from other causes. CONCLUSIONS: In patients with pure teratoma histology at PC-RPLND, mediastinal involvement at presentation and the presence of an elevated AFP level before PC-RPLND predicted an unfavorable outcome. The absence of mediastinal involvement and normal AFP level, however, did not confirm freedom from disease recurrence. Patients who had teratoma at the time of PC-RPLND remained at considerable risk for disease progression because of the unpredictable nature of teratoma and the presence of unrecognized, active germ cell disease outside the retroperitoneum.

KW - Outcome

KW - Postchemotherapy

KW - Predictors

KW - Retroperitoneal lymph node dissection

KW - Teratoma

UR - http://www.scopus.com/inward/record.url?scp=63449114244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449114244&partnerID=8YFLogxK

U2 - 10.1002/cncr.24145

DO - 10.1002/cncr.24145

M3 - Article

C2 - 19156903

AN - SCOPUS:63449114244

VL - 115

SP - 1310

EP - 1317

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -